Perez-Belmonte, Luis MSanz-Canovas, JaimeSalinas, AlejandroGarcia-Klepzig, Jose LuisMendez-Bailon, ManuelGomez-Huelgas, Ricardo2023-05-032023-05-032021-10-22Pérez-Belmonte, L. M., Sanz-Cánovas, J., Salinas, A., Garcia-Klepzig, J. L., Méndez-Bailón, M., & Gómez-Huelgas, R. (2022). Adverse outcomes in patients with heart failure admitted for COVID‑19 in association with the use of renin-angiotensin‑aldosterone system inhibitors. Polish archives of internal medicine, 132(1), 16126.http://hdl.handle.net/10668/21747Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a global health crisis [1]. Patients with cardiovascular disease seem particularly susceptible to severe COVID-19 [2]. Among patients hospitalized for COVID-19, heart failure (HF) has been reported as a factor associated with potential risk for worse outcomes [3,4]. However, to date, specific data on the clinical profile, course, and prognosis of patients with a history of HF are limited [4-6].enAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/Angiotensin Receptor AntagonistsCOVID-19Heart FailureHumansRenin-Angiotensin SystemSARS-CoV-2research article34674519open accessInsuficiencia cardíacaPronósticoCoronavirusEnfermedades cardiovascularesSalud global10.20452/pamw.161261897-9483https://www.mp.pl/paim/en/node/16126/pdf